Premium
Cholecalciferol Repletes Vitamin D Deficiency in Kidney Transplant Recipients (KTR's) with Hyperparathyroidism
Author(s) -
Terebelo Sima,
Markell Mariana
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.218.4
Subject(s) - medicine , cholecalciferol , creatinine , vitamin d deficiency , hyperparathyroidism , vitamin d and neurology , endocrinology , secondary hyperparathyroidism , renal function , population , gastroenterology , urology , parathyroid hormone , calcium , environmental health
Vitamin D deficiency (25OHD2 levels ≤ 25 ng/ml) and hyperparathyroidism are common in KTR's, making hypercalcemia a concern when using active Vit D products. We studied 19 stable hyperparathyroid KTR's, with creatinine 1.53±0.4 mg/dl, and hypovitaminosis D, mean 25‐0HD 16.3±3.8ng/ml. Mean age was 45.9±11.1, months since transplant 39.6±33.4 mos., BMI 33.1±8.9. There were 68% women (13), 84% Afro‐Caribbean (16). Mean intact PTH value was 188.6±80.0 pg/ml, serum Ca 9.7±0.4 mg/dl, PO4 2.8±0.4 mg/dl. Patients received 1000U of Cholecalciferol per day for 6 mos. No pt developed hypercalcemia. 16 pts completed treatment. Adherence by pill count was 0.9±0.2 (Dispensed‐returned/expected consumption). After 24 wks there was a significant difference in 25OHD2 level (30.4±1.8 vs baseline) that was due to increased D3 (p<0.0001). Intact PTH fell but was not significant (137.0±19.4 vs 178.9±15.6, p=0.057). There was no difference in serum Ca, PO4, Mg or Creatinine. We conclude in our population: 1. Cholecalciferol is well tolerated with excellent adherence. 2. Treatment for 24 weeks repletes the majority of patients. 3. There is a trend toward improvement in hyperparathyroidism. 4. There was no effect on Ca, PO4, Mg or kidney function. 5. Long‐term effect on bone disease remains to be studied.